Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Meaghan Wall
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gretchen Poortinga
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kym L. Stanley
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph K. Lindemann
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Bots
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Chan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan J. Bywater
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn M. Kinross
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan V. Astle
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Waldeck
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine M. Hannan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jake Shortt
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Smyth
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott W. Lowe
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross D. Hannan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard B. Pearson
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricky W. Johnstone
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grant A. McArthur
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-12-0404 Published January 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2012 to January 2021

AbstractFull-text HTMLPDF
Total669637952196

Cited By

Article Information

Volume 3, Issue 1, pp. 82-95

DOI 
https://doi.org/10.1158/2159-8290.CD-12-0404
PubMed 
23242809

Published By 
American Association for Cancer Research
Print ISSN 
2159-8274
Online ISSN 
2159-8290
History 
  • Received July 30, 2012
  • Revision received October 22, 2012
  • Accepted October 23, 2012
  • Published first December 14, 2012.

Article Versions

  • Previous version (December 14, 2012 - 06:45).
  • Previous version (December 17, 2012 - 09:36).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2012 American Association for Cancer Research.

Author Information

  1. Meaghan Wall1,3,4,
  2. Gretchen Poortinga1,3,
  3. Kym L. Stanley1,
  4. Ralph K. Lindemann1,13,
  5. Michael Bots1,
  6. Christopher J. Chan1,9,
  7. Megan J. Bywater1,
  8. Kathryn M. Kinross1,
  9. Megan V. Astle1,
  10. Kelly Waldeck1,
  11. Katherine M. Hannan1,
  12. Jake Shortt1,3,
  13. Mark J. Smyth1,6,7,
  14. Scott W. Lowe11,12,
  15. Ross D. Hannan1,5,7,8,10,
  16. Richard B. Pearson1,5,7,8,
  17. Ricky W. Johnstone1,6,7 and
  18. Grant A. McArthur1,2,3,6,7
  1. Authors' Affiliations:1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
  1. Corresponding Author:
    Grant McArthur, Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia. Phone: 61-3-9656-1954; Fax: 61-3-9656-3717; E-mail: grant.mcarthur{at}petermac.org
  1. M. Wall and G. Pootinga contributed equally to this work.

View Full Text
PreviousNext
Back to top
Cancer Discovery: 3 (1)
January 2013
Volume 3, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Cancer Discov January 1 2013 (3) (1) 82-95; DOI: 10.1158/2159-8290.CD-12-0404

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Cancer Discov January 1 2013 (3) (1) 82-95; DOI: 10.1158/2159-8290.CD-12-0404
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Methods
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • YTHDF2 Maintains Glioblastoma Stem Cells
  • Genomic Profiling in FGFR2-Rearranged Cholangiocarcinoma
  • Organoid Platform for Developing Ovarian Cancer Therapies
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement